by Christine L. Kempton, and Amanda B. Payne

Slides:

Advertisements

Similar presentations

A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in.

Advertisements

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

Why not the liver instead of the kidney?

GVHD-associated immunodeficiency: soil or seed?

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis by Samantha C. Gouw, H. Marijke.

Hydroxyurea makes inflammation “just right”?

TCR-MHC-peptide(s): in vivo veritas

Triple play of H pylori in ITP

Volume 78, Issue 2, Pages (July 2010)

It's all in the timing by Linda J. Bendall Blood

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

BRAF inhibitor: targeted therapy in hairy cell leukemia

Rethinking bioactivity of FLT3 inhibitors

T regulatory cells turn on T regulatory cells

Important port for SHIP-1 at Dok-3

by Corey S. Cutler, John Koreth, and Jerome Ritz

Targeting kinases in CML CLL

Deep mining of the RBC proteome

How we choose factor VIII to treat hemophilia

by Ernest Beutler Blood Volume 98(9): November 1, 2001

An actuarial GPS for hemophilic longevity

Has the T cell bitten off more than it can chew?

by Sabah Sallah, and Jim Y. Wan

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

ROCK and Rho(ll) in bone marrow

Latest lymphoma classification is skin deep

HU for acute treatment of sickle VOC?

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the.

Activity of eltrombopag in severe aplastic anemia

Immunotherapy for acute lymphoblastic leukemia: from famine to feast

Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non–severely ill patients

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

by Katalin Kis-Toth, Gaurav Manohar Rajani, Allison Simpson, Kate L

by Alex Aleshin, and Peter L. Greenberg

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB (Alliance)‏ by John C. Byrd, Amy S. Ruppert,

by J. Michael Soucie, Paul E. Monahan, Roshni Kulkarni, Barbara A

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

by Kaiwen Chen, Matthew P. Cheng, Sarah P

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Volume 2(Supplement 1):1-3

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma by Sham Mailankody, Dickran Kazandjian, Neha Korde,

Accurate, simple, and inexpensive assays to diagnose F8 gene inversion mutations in hemophilia A patients and carriers by Debargh Dutta, Devi Gunasekera,

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,

by Michael R. DeBaun, and Ellen Wright Clayton

by Jens Kjeldsen-Kragh, Thomas L

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.

Overcoming “aspirin resistance” in MPN

Volume 2(Supplement 1):39-41

Proposed model of molecular pathogenesis in the development and progression of major subtypes of MCL. Precursor B cells usually with but sometimes without.

Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis by Rasha Khatib, Maja Ludwikowska, Daniel.

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Resistance mechanism for ibrutinib in marginal zone lymphoma

Impact of age on clinical risk scores in follicular lymphoma

Anti-CD20-IL-21 fusokine: the tail wags the dog

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

by Lucy A. Godley, and Akiko Shimamura

by Suman L. Sood, Dunlei Cheng, Margaret Ragni, Craig M

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

Initial treatment of CLL: integrating biology and functional status

Normal pathway of B12 absorption and cellular uptake.

by Jennifer N. Brudno, and James N. Kochenderfer

Volume 2(Supplement 1):4-7

Presentation transcript:

by Christine L. Kempton, and Amanda B. Payne HLA-DRB1–factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study by Christine L. Kempton, and Amanda B. Payne BloodAdv Volume 2(14):1750-1755 July 24, 2018 ©2018 by American Society of Hematology

Professional illustration by Patrick Lane, ScEYEnce Studios. Christine L. Kempton, and Amanda B. Payne Blood Adv 2018;2:1750-1755 ©2018 by American Society of Hematology

Flow diagram of subject inclusion. Christine L. Kempton, and Amanda B. Payne Blood Adv 2018;2:1750-1755 ©2018 by American Society of Hematology

Location and frequency of mutations on factor 8. Christine L. Kempton, and Amanda B. Payne Blood Adv 2018;2:1750-1755 ©2018 by American Society of Hematology